BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld Asia
Home
» Xention Inks Servier Option Deal for Ion Channel Modulator
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Xention Inks Servier Option Deal for Ion Channel Modulator
Oct. 9, 2013
By
Nuala Moran
No Comments
LONDON – Xention Ltd. has taken a major step forward, out-licensing its atrial fibrillation treatment XEN-DO103 in a $163 million-plus joint development agreement in which the UK biotech will retain full rights to the product in the U.S. and Japan.
BioWorld Asia